Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; TAFI; thrombin-activatable fibrinolysis inhibitor; TAFIa; activated thrombin-activatable fibrinolysis inhibitor; SDS; sodium dodecyl sulfate; PolyP; polyphosphate; PPACK; H-D-Phe-Pro-Arg-chloromethylketone; CMC; critical micelle concentration; Carboxypept
مقالات ISI مهارکننده فیبرینولیز فعال فعال ترومبین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; PFP; platelet-free plasma; PPP; platelet-poor plasma; PRP; platelet-rich plasma; UFP; ultra-free plasma; TAFI; thrombin-activatable fibrinolysis inhibitor; TF; tissue factor; Blood coagulation; Spatial thrombus formation; Thrombin travelling waves;
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; A488-FDP; AlexaFluor488-containing fibrin degradation products; AUC; area under curve; CCCP; carbonyl cyanide chlorophenylhydrazone; CR; clot retraction; CT; clotting time; DIC; disseminated intravascular coagulation; FITC; fluorescein isothiocyanate; GP;
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; Cardiovascular disease; Coronary heart disease; Meta-analysis; Stroke; Thrombin-activatable fibrinolysis inhibitor;
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; DENV; dengue virus; DF; dengue fever; DHF; dengue hemorrhagic fever; TAT; thrombin-antithrombin complex; TM; thrombomodulin; NS1; nonstructural protein-1; FL; full-length; tr; thrombin-cleaved; OPN; osteopontin; RGD; arginine-glycine-aspartic acid; TAFIa;
Fibrinolytic potential of DS-1040, a novel orally available inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; APTT; activated partial thromboplastin time; TAFIa; activated thrombin-activatable fibrinolysis inhibitor; PCI; carboxypeptidase inhibitor from potato tuber; CPN; carboxypeptidase N; PRP; platelet-rich plasma; PT; prothrombin time; rt-PA; recombinant tiss
IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; Inflammatory breast cancer; Carboxypeptidase B2; Thrombin-activatable fibrinolysis inhibitor; Interleukin-10; Thrombomodulin; Macrophages; Lymphovascular invasion;
Haplotypes of TAFI gene and the risk of cerebral venous thrombosis - a case-control study
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; CVT; cerebral venous thrombosis; DVT; deep vein thrombosis; PE; pulmonary embolism; TAFI; thrombin-activatable fibrinolysis inhibitor; SNP; single nucleotide polymorphism; VTE; venous thromboembolism; OR; odds ratio; CI; confidence interval; OC; oral cont
Whole blood clots are more resistant to lysis than plasma clots - greater efficacy of rivaroxaban
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; DVT; Deep venous thrombosis; PPP; Platelet-poor plasma; PRP; Platelet-rich plasma; RBCs; Red blood cells; TAFI; Thrombin-activatable fibrinolysis inhibitor; TF; Tissue factor; t-PA; Tissue plasminogen activator; VTE; Venous thromboembolism; WB; Whole bloo
Serum des-R prothrombin activation peptide fragment 2: A novel prognostic marker for disseminated intravascular coagulation
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; aPTT; activated partial thromboplastin time; CI; confidence interval; des-R F2; des-R prothrombin activation peptide fragment 2; DIC; disseminated intravascular coagulation; ELISA; enzyme-linked immunosorbent assay; HR; hazard ratio; PT; prothrombin time;
Regular ArticleRisk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; TAFI; thrombin-activatable fibrinolysis inhibitor; VTE; venous thromboembolism; RFL; recurrent fetal loss; APC; activated Protein C; LAC; lupus anticoagulant; SD; standard deviation; OR; odds ratio; CI; confidence interval; SNPs; single-nucleotide polymor
Effects of Raloxifene on Endothelial Function and Hemostasis in Women With Ischemic Heart Disease
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; FMD; Flow-mediated dilatation; PAI-1; Plasminogen activator inhibitor type-1; PAP; Plasmin/antiplasmin; SERM; Selective estrogen receptor modulator; TAFI; Thrombin-activatable fibrinolysis inhibitor; Endothelium; Coronary disease; Raloxifene; Fibrinolysis
Influence of Gestational Age on Fibrinolysis from Birth to Postnatal Day 10
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; ELISA; Enzyme-linked immunosorbent assay; GMH-IVH; Germinal matrix hemorrhage-intraventricular hemorrhage; PAI; Plasminogen activator inhibitor; PVHI; Periventricular hemorrhagic infarction; TAFI; Thrombin-activatable fibrinolysis inhibitor; t-PA; Tissu
Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; Polycystic ovary syndrome; thrombin-activatable fibrinolysis inhibitor; carotid intima-media thickness; cardiovascular disease;
Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; Thrombin-activatable fibrinolysis inhibitor; genetic polymorphisms; recurrent pregnancy loss
Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI)
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; Thrombin-activatable procarboxypeptidase B; proCPB; CPB; Thrombin-activatable fibrinolysis inhibitor; TAFI; Thrombin-thrombomodulin; Thrombin; Inflammation;
Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes : Evidence for normal fibrinolytic state
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; Thrombin-activatable fibrinolysis inhibitor; Global fibrinolytic capacity; Type 1 diabetes; Complications
Common promoter polymorphisms of inflammation and thrombosis genes and longevity in older adults: The cardiovascular health study
Keywords: مهارکننده فیبرینولیز فعال فعال ترومبین; Thrombin-activatable fibrinolysis inhibitor; Longevity; Inflammation; Fibrinolysis; Promoter polymorphism;